文献速递泌尿男性生殖肿瘤

帕博利珠单抗联合恩扎卢胺和雄激素剥夺治疗对比安慰剂联合恩扎卢胺和雄激素剥夺治疗用于转移性激素敏感性前列腺癌:随机双盲III期KEYNOTE-991研究

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.
PubMed 文献 · Ann Oncol · 2025-05-16

KEYNOTE-991研究纳入626例转移性激素敏感性前列腺癌(mHSPC)患者随机接受帕博利珠单抗或安慰剂联合恩扎卢胺和雄激素剥夺治疗(ADT)。主要终点影像学无进展生存(rPFS)未优于安慰剂(HR 1.20,95%CI 0.96-1.49,P=0.9467),总生存(OS)亦未达统计学检验。帕博利珠单抗组≥3级不良事件和严重不良事件发生率更高,皮疹为额外安全性信号。研究因无效而终止。

要点

  • 帕博利珠单抗联合恩扎卢胺和ADT未改善mHSPC患者的rPFS(HR 1.20,95%CI 0.96-1.49)。
  • 帕博利珠单抗组≥3级不良事件和严重不良事件发生率高于安慰剂组。
  • 帕博利珠单抗组任何级别皮疹发生率高于安慰剂组(25.1% vs 9.3%)。

核心结论

  • KEYNOTE-991未达到主要终点,因无效而终止。
  • 在恩扎卢胺和ADT基础上加用帕博利珠单抗与安慰剂相比,≥3级不良事件和严重不良事件发生率更高。
  • 皮疹被确定为帕博利珠单抗联合恩扎卢胺和ADT的额外安全性信号。

研究设计与样本

  • 随机、双盲、安慰剂对照III期KEYNOTE-991研究。
  • 纳入年龄≥18岁、未接受过新一代激素药物的转移性激素敏感性前列腺癌(mHSPC)患者。
  • 按1:1随机分配至帕博利珠单抗200 mg静脉注射或安慰剂每3周一次(最多35个周期),联合口服恩扎卢胺160 mg和持续ADT。
  • 2020年3月2日至2021年8月9日期间,626例分配至帕博利珠单抗联合恩扎卢胺和ADT组,625例分配至安慰剂联合恩扎卢胺和ADT组。
  • 主要终点为影像学无进展生存(rPFS)和总生存(OS);安全性为次要终点。

主要发现

  • 首次 interim 分析时中位随访21.1个月(范围14.8-32.0个月)。
  • rPFS未优于安慰剂:两组中位值均未达到,HR 1.20(95%CI 0.96-1.49),P=0.9467。
  • 两组中位OS均未达到,HR 1.16(95%CI 0.88-1.53),按多重性策略未进行正式统计学检验。
  • 帕博利珠单抗组 vs 安慰剂组:≥3级不良事件发生率61.9% vs 38.1%,严重不良事件发生率40.3% vs 23.2%。
  • 帕博利珠单抗组任何级别皮疹发生率25.1%,安慰剂组为9.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC. PATIENTS AND METHODS: Eligible participants were aged ≥18 years with next-generation hormonal agent-naive mHSPC. Participants were randomly assigned (1 : 1) to receive intravenous pembrolizumab 200 mg or placebo every 3 weeks for ≤35 cycles, with oral enzalutamide 160 mg and continuous ADT. Primary endpoints were radiographic progression-free survival (rPFS) and overall survival (OS). Safety was a secondary endpoint. RESULTS: Between 2 March 2020 and 9 August 2021, 626 participants were randomly assigned to receive pembrolizumab plus enzalutamide and ADT and 625 participants to receive placebo plus enzalutamide and ADT. At the first interim analysis, the median follow-up was 21.1 months (range 14.8-32.0 months). rPFS was not superior with pembrolizumab versus placebo [median not reached in both arms; hazard ratio (HR) 1.20, 95% confidence interval (CI) 0.96-1.49, P = 0.9467]. Median OS was not reached in either arm (HR 1.16, 95% CI 0.88-1.53; not formally statistically tested as per the multiplicity strategy). Grade ≥3 adverse events (AEs) and serious AEs (SAEs) were reported in 61.9% versus 38.1% and 40.3% versus 23.2% of participants in the pembrolizumab versus the placebo arm, respectively. Any-grade rash occurred at a higher frequency with pembrolizumab (25.1%) versus placebo (9.3%). CONCLUSIONS: KEYNOTE-991 did not meet its primary endpoint and was stopped for futility. The addition of pembrolizumab to enzalutamide and ADT was associated with higher frequencies of grade ≥3 AEs and SAEs than with placebo. Rash was identified as an additional safety signal with pembrolizumab plus enzalutamide and ADT.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gratzke C, Özgüroğlu M, Peer A, et al. Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study. Ann Oncol. 2025. PMID: 40383194. doi:10.1016/j.annonc.2025.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。